[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

George Scorsis, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock. The award is reported as direct beneficial ownership by the reporting person.

One-third of the RSUs vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning up to 29,240 common shares may be issued to satisfy the award over three years if vesting conditions are met. The grant is a standard equity compensation award for a board member with a multi-year retention schedule.

Positive

• 29,240 RSUs granted to director George Scorsis
• Vesting schedule is explicit: one-third on 08/08/2026, 08/08/2027 and 08/08/2028

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director equity grant of 29,240 RSUs with three-year vesting; governance impact appears standard and non-disruptive.

The Form 4 shows a non-derivative-based equity compensation award in the form of 29,240 Restricted Stock Units granted to director George Scorsis on 08/08/2025. The RSUs are direct beneficial ownership and vest one-third annually on 08/08/2026, 08/08/2027 and 08/08/2028. From a governance perspective, this is a typical retention and alignment mechanism for a board member. The filing does not disclose any accelerated vesting triggers or related-party transaction terms beyond the basic grant and schedule, so material governance concerns are not evident from the document alone.

Compensation Analyst

TL;DR: A standard RSU award totaling 29,240 units with staged vesting over three years; compensation outcomes depend on settlement terms not detailed here.

The report specifies 29,240 RSUs, each converting to one share upon vesting, exercisable under a schedule of one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028. The conversion price is shown as $0, consistent with RSUs that settle in shares rather than requiring purchase. The Form 4 indicates direct ownership post-grant. The filing lacks additional compensation plan details such as performance conditions, settlement timing, or withholding treatment, so assessment of total cost or dilutive impact to shareholders cannot be quantified from this document alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scorsis George

(Last) (First) (Middle)

C/O SHUTTLE PHARMACEUTICALS HOLDINGS

401 PROFESSIONAL DRIVE, SUITE 260

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/08/2025		A		29,240		(2)	(2)	Common Stock	29,240	$0	29,240	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.

2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.

	/s/ George Scorsis	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did George Scorsis receive according to the SHPH Form 4?

The Form 4 reports a grant of 29,240 Restricted Stock Units (RSUs) to George Scorsis.

When do the RSUs awarded to the SHPH director vest?

The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027, and one-third on 08/08/2028.

How many shares will be issued if all RSUs to George Scorsis vest?

Each RSU represents the right to one share, so 29,240 potential common shares could be issued upon full vesting.

Is the beneficial ownership reported as direct or indirect in the SHPH filing?

The Form 4 shows the RSUs as direct (D) beneficial ownership for the reporting person.

Was this Form 4 filed by a single reporting person for SHPH?

Yes. The document indicates the form was filed by one reporting person.